smrt deal long
happen even held confer call
discuss announc acquisit
pleas find updat thesi well detail note pleas email
us want updat pf model
thesi updat straight forward deal
imagin long read sequenc forev promis
highli complementari exist sb portfolio
tech also way readi prime time nanopor
opinion continu struggl accuraci stabil
technic hurdl furthermor think upcom launch
notabl promis updat bring
human genom cost manag vs
previous coupl develop commerci might
forese materi uptick revenu help cushion
blow dilut calc furthermor would
argu like duplic opex also volum
ramp zmw notabl uptick current
sit abl long term addit
would note like growth accret much
help push long term compound-annual-growth-rate
thu roll togeth low risk bet sale
cap long watch space
afar given engin know-how technic masteri
would assum opportunist time indic
confid abil execut ahead key catalyst
like simpl equiti price appeal
help de-risk key commerci launch subscal salesforc
mix lack access capit go tough
road ahead despit promis technolog thu see
perfect marriag believ right owner
think process may elong struggl see issu
ftc especi client protest unlik given mid-
year close lower ep dilut
note underli ep remain unchang
view guid stand-alone updat dilut upon
close tweak pt simpli math cash
util today vs potenti gener futur take time
get asset corpor margin reiter outperform
acquir long-read tech
largest acquisit sinc solexa
long-read complementari role short-read
offer insight long rang rearrang
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
structur variant haplotyp challeng
long-read particularli applic de novo assembl
space current play
pacbio recent releas new sequenc enzym softwar
updat earlier year w/ new protocol reagent algo
doubl previou output current ecosystem
highest read accuraci long-read platform
improv workflow remov need larg
quantiti high molecular weight dna
zero-mod waveguid zmw chip
expect earli next year increas
pacb reduct cost per gigabyt provid access
rang divers higher scale sampl cheaper price
particularli excit clinic applic
potenti integr data machin
long-read competit big concern pacbio
preferenti due accuraci scalabl econom small
amount materi requir
sequenc pacbio term new speci unlock new
market sequenc execut machin
sale team sell box current
channel need specialist overlay team
deal wont close mid-next year
move earlier everybodi els
confid highli qualifi buyer
concern regul long-read
complementari short-read
current play long-read
expect deal dilut benefit tax
rate loss
beyond anticip gm opex synergi
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin novemb
analyst luke sergott ross muken primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
